Unproven stem cell therapies: is it my right to try? by Riva, Luciana et al.
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
179
Key words
• stem cells
•  compassionate use 
trials
• trust
• medical tourism 
Unproven stem cell therapies:  
is it my right to try?
Luciana Riva1, Laura Campanozzi2, Massimiliano Vitali3, Giovanna Ricci4  
and Vittoradolfo Tambone2 
1Unità di Bioetica, Istituto Superiore di Sanità, Rome, Italy 
2Istituto di Filosofia dell’Agire Scientifico e Tecnologico – FAST, Università Campus Bio-Medico di Roma, 
Rome, Italy 
3Policlinico Universitario Campus Bio-Medico, Rome, Italy 
4Scuola di Giurisprudenza, Università degli Studi di Camerino, Camerino, Italy 
Ann Ist Super Sanità 2019 | Vol. 55, No. 2: 179-185
DOI: 10.4415/ANN_19_02_10
Abstract
Background. Nowadays one of the most critical aspects of innovative cell-based thera-
pies is the unregulated industry, as it is becoming a competitor of the regulated system. 
Many private clinics, worldwide, advertise and offer cell-based interventions treatments 
directly to the consumer and this poses a risk to both vulnerable patients and health sys-
tems. Several countries have implemented Compassionate Use Programmes (CUP) that 
provide patients with medicines that have not yet completed the approval pathway, in 
the event that no reasonable alternative exists. Recently, in the public discourse, compas-
sionate use has been increasingly associated with a patient’s right to try. Thus, the aim of 
this study was to assess public knowledge of the clinical trials process with specific refer-
ence to innovative stem cell treatments, and trust in the institutions responsible for regu-
latory activities. We also asked people about their “right” to use unregulated therapies.   
Methods. We developed an ad hoc questionnaire on three main areas of concern and ad-
ministered it to 300 people in the patient waiting room at an Italian university hospital. 
Results. Our findings suggest that people have a good knowledge of the clinical trials 
process and trust in healthcare institutions. Nonetheless, one person in two believes it is 
a right to use unregulated therapies. 
Conclusions. We stress the need, in the age of cellular therapies, for a commitment to 
support vulnerable patients and to strengthen awareness among the public about the 
substantial boundary that differentiates experimental therapies from unproven therapies. 
There should not be a “right to try” something that is unsafe but rather approved treat-
ments and in line with good clinical practice. The trend, which emerged on this issue 
from our study, is quite different, confirming the urgent need to improve health informa-
tion so that it is as complete as possible.
INTRODUCTION
Worldwide, innovative cell-based therapies have rep-
resented a considerable challenge for regulatory systems 
over the last decade. Within this field characterized by 
a rapid technological advancement, the products of the 
discoveries of medicine and biology have become more 
and more “therapeutic options” advertised and offered 
by private producers directly to the consumer. Over the 
last two decades, a boom in for-profit clinics offering 
stem cell therapy directly to patients for a wide range of 
diseases has occurred and tragically, some patients died 
from dangerous injections of cells [1]. 
Within a regulated context, the responsibility for the 
assessment of safety of treatment pertains to regulatory 
agencies; outside this setting, patients do not have an 
adequate guarantee of protection. The European Com-
mittee for Advanced Therapies (CAT) has expressed its 
views on this matter in many documents, with particu-
lar “concern about a phenomenon known as stem-cell 
tourism in which severely ill patients travel to clinics 
around the world where unauthorized stem-cell-based 
treatments are offered in the absence of rigorous scien-
tific and ethical requirements” [2]. The CAT has strong-
ly encouraged the development of stem-cell-based me-
dicinal products in approved and high-quality research 
programs [3]. 
The protection of patients from ineffective and risky 
therapies is an important issue that requires legal, ethics 
and public health considerations. Currently, most stem 
cell therapies are experimental and many scientists do 
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not know exactly how they work and how safe they 
are. In turn, the clinical application of these products, 
which has only just begun, is raising numerous ethical 
questions that the International Society for Stem Cell 
Research (ISSCR) has recently examined in detail in 
the “Guidelines for Stem Cell Research and Clinical 
Translation” [4, 5]. Specifically, the transparency of the 
clinical data, the accurate and effective communication 
in the process of informed consent are crucial elements, 
especially in the early phase of trials with humans, when 
there should be particular care in avoiding overestima-
tion of benefits or therapeutic misconceptions [5]. For 
example, people may not clearly understand the signifi-
cance that a regimented experimentation process as-
sumes for the safety and protection of health and may 
be confused about the readiness of a technology for 
clinical application. 
In the era of biotechnologies and great attention of 
media to these new therapies, which often creates dis-
proportionate hope among people, these considerations 
are highly relevant for their implications. Patients and 
their families, especially if they have a very serious health 
condition, are vulnerable and must be protected as such. 
For the first time, the Guidelines focus on the impor-
tance of the communication process to the public, rec-
ommending timely correction of every possible mislead-
ing public representation. Inaccurate portraits of stem 
cell research may have severe consequences, including 
misinforming policy debate, and premature clinical use 
of unapproved treatments [6, 7]. An integrated effort 
is needed involving diverse actors, such as researchers, 
institutions and specialists in scientific communication 
to safeguard the public from misinformation. 
The right to health
Stem cell therapies have become a matter of contro-
versy in public debate and in legal decisions. There have 
also been cases in which patients opposed the State for 
access to experimental therapies. In 2014, Italy was the 
subject of a highly controversial legal battle, Durisotto vs 
Italy, also known as the “Stamina case”, about an alleged 
innovative stem-cell therapy. The controversial and 
broad debate that developed around this case focused 
on the acceptability of providing treatment not based on 
scientific evidence when a patient’s request is advanced 
as a last hope of healing or relief from a condition of 
suffering. The stamina treatment, which had been ad-
ministered to numerous patients starting in 2008 in 
public hospital, was based on the use of mesenchymal 
stem cells (MSCs) and intended for the treatment of 
neurodegenerative diseases. Unfortunately, as was then 
demonstrated, there was no study protocol upstream, 
with one exception which presented serious flaws and 
omissions involving a procedure which did not comply 
with any Good Manufacturing Practices (GMP) [7, 8]. 
On 6 May 2014, the European Court of Human 
Rights (ECHR) ruled on the patient’s right to decide 
to resort to unproven treatments – stem cell therapies – 
in the absence of other therapeutic possibilities, in the 
wake of the Durisotto vs Italy case. Mr. Durisotto ap-
plied to the ECHR following the refusal by the Italian 
courts to authorize compassionate therapy (specifically, 
the “Stamina” method) to treat his daughter’s degenera-
tive cerebral illness. The European Court rejected the 
patient’s claim. In particular, it declared the application 
inadmissible under Article 8 of the European Conven-
tion on Human Right (right to respect for private and 
family life) stating that “the interference in the right to 
respect for the private life, represented by the refusal to 
grant the request for medical therapy, could be consid-
ered as necessary in a democratic society”. The prohibi-
tion on access to the therapy in question “pursued the 
legitimate aim of protecting health and was proportion-
ate to that aim” [9]. 
If the protection of the right to health is attributed to 
the legislator, access to a new therapy has to be regu-
lated by healthcare norms that deﬁne all the conditions 
of the procedure. In other words, healthcare authorities 
must decide on the scientific validity and on the appro-
priateness of the treatment. 
In media discourse, the reference to compassion, hope 
and right are often invoked and associated with the 
request for access to innovative or experimental pro-
cedures. As we will see later, the definition “compas-
sionate use”, used today even within institutional and 
regulatory documents, can be easily misunderstood 
regarding its exact meaning [10, 11]. However, in no 
way does it indicate the possibility of accessing any 
treatment offered by anyone without prior sharing of 
the rationale within a broader scientific community. It 
does not mean that any attempt is admissible: a choice 
made on the emotional wave of despair and hope may 
not be the best choice and could even be detrimental 
to the dignity of the person’s own life if, for example, it 
involves avoidable or disproportionate suffering. 
The Right To Try (RTT) movement
In recent years, many US States, in the face of great 
pressure from public movements, patient advoca-
cies and think tanks, have passed “Right to Try” laws, 
which give terminally ill patients access to experimen-
tal compounds that have passed phase I testing [12]. 
These laws provide that a patient who wants to try an 
experimental drug can contact the pharmaceutical 
company directly, cutting out the “filter” of the com-
petent authority, the Food and Drug Administration 
(FDA). Those against the Right to Try (RTT) laws gen-
erally argue that they are not a boon for patient rights, 
but that they rather dismantle the safety system that 
protects people. Liberal access to unproven therapies 
could have a negative impact on individual patients 
in a state of vulnerability, by offering false hope that 
leads to increased suffering. In the US, supporters 
of the RTT have used emotionally charged stories in 
which someone is dying – a child or parent – to invoke 
access to an experimental drug that might offer salva-
tion. If there is hope that the treatment might work, 
RTT supporters argue, the patient has the right to try 
to preserve his own life. However, patients in very seri-
ous condition might judge risks and potential benefits 
differently than scientists do and they might not sense 
the irrationality of their own hope. 
It should be noted that RTT laws offer not a right 
to try, as suggested in the name, but rather a right to 
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ask for access in order to try. To acclaim and advocate 
a right to try suggests that regulated systems do not 
permit access to experimental treatments, whereas in 
many countries, these systems provide compassionate 
use or expanded access of experimental treatments by 
defining a threshold of scientific evidence and safety 
necessary to support such use or access. In this regard, 
it is useful to stress that there is a difference between 
unproven therapies and unregulated therapies and that the 
treatments administered through compassionate use or 
expanded access programmes are unproven (i.e. not yet 
proven) but regulated. Around this issue, a radical idea 
of care as free choice – with no interference whatso-
ever – to make decisions regarding one’s body seems 
to be emerging. Some authors have referred to a “right 
to self-medication”, by rooting this right in the value of 
autonomy [13].
This radical position reflects either a feeling of dis-
trust in institutions that must protect the interests of 
patients or a more generic statement of freedom of 
choice. Perhaps for some it is a mixture of the two. The 
basic question is: to what extent should the law prevent 
people from taking risks they voluntarily accept.  For 
some, protection at all costs is considered paternalistic, 
a stance that disregards the value of autonomy of the 
individual. 
Regarding these issues, the position expressed by the 
ECHR in Durisotto vs Italy is very clear. It is useful here 
to point out three facts: 
• the ECHR reiterated that it was not to the place 
of the international court to substitute itself for the 
competent domestic authorities in determining the 
level of acceptable risk for patients wishing to have 
access to compassionate therapy in the context of ex-
perimental treatment; 
• the ECHR stated that “The interference in the right 
to respect for one’s private life, represented by the 
refusal to grant the request for medical therapy, could 
be considered as necessary in a democratic society”;
• the protection of the right to health, on the part of 
the legislator, is realized through the non-authoriza-
tion of unsafe or harmful treatments. 
Compassionate use program
Regulation no. 726 /2004 of the European Parliament 
and Council regulates “Compassionate use”, which it 
defines in art. 83, part 2 as “making a medicinal prod-
uct (…) available for compassionate reasons to a group 
of patients with a chronically or seriously debilitating 
disease (…) and who cannot be treated satisfactorily 
by an authorized medicinal product” [14]. In turn, the 
European Medicines Agency (EMA) defines “compas-
sionate use” as a treatment option that allows the use 
of an unauthorized medicinal product, which is under 
development. In Europe, EMA provides recommenda-
tions and guidelines for compassionate use [15] and ev-
ery member state sets its own rules. Currently, a wide 
disparity exists across European member states regard-
ing the procedures of application [16, 17].
Italian law allows compassionate use in some cir-
cumstances in which specific criteria are met.  DM 
7/09/2017 on “Therapeutic use of a medicine subjected 
to clinical trials” regulates access to experimental phar-
macological therapies for use outside a clinical trial, to 
patients suffering from serious, rare or life-threatening 
diseases when, according to the clinician, there are no 
other valid therapeutic alternatives [18].
Innovative therapies, by their nature, are experi-
mental treatments which cannot be evidence-based or 
clinically indicated and may lack a demonstrable safety 
profile. As some authors have highlighted, the primary 
purpose of legislation on innovation, and on medical 
innovation in particular, must be to beneﬁt the indi-
vidual patient [19]. To conduct an open debate on how 
to guarantee “responsible innovation” at a time when 
innovation in cell therapy and regenerative medicine 
is moving into the clinical context is an issue of para-
mount importance. Equally important is the need to 
increase public awareness of the significance of the 
regulated process of clinical experimentation and trust 
in institutions responsible for the control, approval 
and evaluation of the risk-benefit profiles of innovative 
treatments. Against this backdrop, we have conducted 
a pilot survey on a sample of the Italian population to 
assess public knowledge of the clinical trials process 
with specific reference to innovative stem cell treat-
ments. We also asked people about their “right” to use 
unregulated therapies, in order to get a picture of how 
people are potentially vulnerable to undergoing un-
proven therapies and to have some indication of what 
the right to try means for them.
MATERIALS AND METHODS 
A bibliographic search in the PubMed database was 
conducted to verify the presence of international stud-
ies on attitudes among the public towards both the 
use of unregulated therapies and general knowledge 
of the clinical trial process. No questionnaires related 
precisely to our query was found. We chose to carry 
out a survey on a sample of the population using an 
ad hoc questionnaire developed through the methodol-
ogy of an expert focus group. Five experts took part 
in the focus group: a bioethicist, a bio-statistician, a 
philosopher of science, an expert in health professions 
and a psychologist. The issues that emerged from the 
working group discussions were divided into three 
conceptual blocks representing three topics under in-
vestigation: 1) public information on the clinical trial 
process; 2) specific information on treatments based 
on stem cells; 3) general trust in the governing bodies 
and institutions responsible for the control and regula-
tion of the clinical trial process. Based on the experts’ 
suggestions, we formulated ten questions for each the-
matic area and then asked the focus group members 
to indicate through a vote the most effective ones. The 
resulting questionnaire used for the survey consisted of 
16 questions (6 for the first block, 4 for the second and 
6 for the third), with an introductory section consisting 
of five items for sample stratification (sex; age; level of 
education; work in the health sector or not; medical 
sector in which the patient was seeking care). The sam-
ple for the study was randomly recruited among people 
who were in the patient waiting room at the Campus 
Bio-Medico University Hospital in Rome, Italy. The 
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questionnaire was distributed to a total of 300 people 
including patients and “companions” (persons accom-
panying patients). The questionnaire was anonymous 
and the estimated compilation time was approximately 
4 minutes. Participants could stop filling out the ques-
tionnaire at any time. The data extrapolated from the 
returned questionnaires was placed in an electronic 
database built specifically for collection. The data was 
verified and analysed through the statistical package 
SPSS v24 copyright. A first descriptive analysis was 
conducted for each individual item. Then we proceeded 
to make comparisons among the responses to the vari-
ous items by using the chi-square test. Differences with 
P <0.05 were considered statistically significant. When 
answers to different questions are been examined, the 
frequency of the correct answers is compared with the 
sum of the frequencies of the wrong answers across the 
different questions. The significant results of the study 
are reported and discussed in the next section. 
RESULTS 
A total of 219 questionnaires were returned (73% of 
the total responded). The descriptive analysis showed 
that the sample is homogeneous as regards the strati-
fication variables with the exception of the level of 
education (67.12% of the sample had completed high 
school but not studied beyond that) and the type of 
occupation (86% of the responders are not healthcare 
professionals) (Table 1). On the questions concerning 
knowledge of the clinical trial process, 77.63% of the 
sample showed that they knew what a clinical trial is, 
answering that it is a study authorized by the institu-
tions responsible for public health policies. 74.43% 
correctly answered the question about whether an 
investigational drug can be administered to humans. 
52.05% answered that the experimentation of a new 
drug or treatment lasts on average from 7 to 10 years. 
The data showed that those who correctly answer ques-
tions about the clinical trial process have much more 
confidence that regulation protects the interests of pa-
tients compared to those who have no knowledge of 
the trial processes (P <0.05). Only 33.33% of the sam-
ple knew the meaning of “compassionate use” of a drug 
and 52.51% responded that they did not know if such 
use is possible in Italy. To the question “Do you think 
it is a right of patients to use treatments not autho-
rized by the institutions responsible for public health 
policies”, 43.38% of the sample replied no, 41.55% yes 
and 15.07% did not know. 95.89% of the sample re-
sponded they had heard of stem cell-based treatments. 
Answers to the question about the possibility of using 
stem cell-based treatments in Italy were homogeneous-
ly distributed (36.99% yes; 29.22% no; 33.79% I do not 
know). When asked about the number of pathologies 
for which stem cell treatments have proven effective, 
42.47% responded “I don’t know”, 22.83% responded 
“more than 100 pathologies” and 33.79% responded 
“a very small number of pathologies”. 72.60% of the 
sample said they have heard of patients going abroad 
to undergo treatment with stem cells not authorized in 
Italy. The analysis showed no significant correlation be-
tween the opinion about the use of unregulated drugs 
and the medical sector in which the patient was seek-
ing care. Answers regarding trust in the institutions re-
sponsible for regulatory activities were positive in refer-
ence to the following: Italian Medicine Agency (AIFA) 
75.9%; Ministry of Health 71.3%; Italian National In-
stitute of Health (Istituto Superiore di Sanità – ISS) 
79.9%; World Health Organization (WHO) 89.5%; 
Ethics Committees 76.3%. In addition, a statistically 
significant correlation was found (P <0.05) between re-
sponses to the question on trust in institutions and the 
question of trust in the fact that regulation of the pro-
cess protects the interests of patients (Table 2). Only 12 
of the 16 items in the questionnaire are shown in the 
table. We decided to omit four questions related to the 
third block because they showed no significant correla-
tion. We believe this is probably due to the complexity 
of the construct formulation.
DISCUSSION 
The results show that the people interviewed had a 
good general knowledge of the clinical trial process.  In 
fact, the number of correct answers to the questions 
Table1 
Overview of the  responders to the pilot survey on the public’s 
knowledge about. perception of. and trust in the testing pro-
cess of a new drug or treatment
Characteristics 
Total (N) 219 
Sex (%)
Female 50.68
Male 49.32
Age (Mean, min-max)
Male 40 (18-82)
Female 44 (19-80)
All 42 (18-82)
Education (%)
None 1.37
Primary school 5.02
Secondary school 67.12
University (undergraduate) 22.83
Master/PhD 3.66
Occupation in healthcare setting (%)
Yes 14.16
No 85.84
Type of respondent (%)
Patient 43.38
Companion 56.62
Medical field of the the patient’s appointment (%)
Diagnostic 58.90
Surgical area 22.84
Onco-hemathologic 18.26
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Table 2 
Answers to the questionnaire items divided by thematic blocks 
Blocks Final number (%) 
Total 219 
Block 1 
What is in your opinion a “clinical trial”?
A study authorized by the institutions responsible for public health policies
A study not yet authorized by the institutions responsible for public health policies
The administration of an innovative drug or treatment outside of a hospital facility
I don’t know
77.62
15.53
5.02
1.83
Is it possible to administer an investigational drug to human beings?
Yes
No
I don’t know
74.42
15.53
10.05
How long do you think  the testing process is for the development of a new drug or treatment ?
Two/three months
One year
Between seven and ten years
I don’t know
1.37
30.14
52.05
16.44
Which of the following definitions of “compassionate use” of a drug is, in your opinion, most correct? 
Use of a drug outside the testing process
Use of a drug outside the national regulatory procedures 
Use of a drug while the trial is not over yet 
I don’t know
10.97
21.00
33.33
34.70
Is the compassionate use of a drug possible in Italy?
Yes
No
I don’t’ Know
17.35
30.14
52.51
Block 2
Have you ever heard of stem cell treatments?
Yes
No
I don’t know 
95.89
1.37
2.74
In Italy it is possible to use stem cell therapy?
Yes
No
I don’t know
36.99
29.22
33.79
Are there diseases for which stem cell treatments have proven effective?
Yes. more than a hundred different diseases 
Yes. a very small number of diseases
No
I don’t know
22.83
33.79
0.91
42.47
Have you ever heard of patients who travel to foreign countries to undergo stem cell-based treatments that 
are not authorized in Italy?
Yes
No
72.60
27.40
Do you believe it is a right of patients to use treatments that have not been authorized by the competent 
authorities?
Yes
No
I don’t know 
41.55
43.38
15.07
Block 3
You can vote from -3 to +3 (-3 = no trust +3 = great trust) to express your confidence in regulatory activity 
of clinical trials of the following institutions*
Italian Medicines Agency (AIFA)
Ministry of Health
Italian National Institute of Health (ISS)
World Health Organization (WHO)
Ethical Committees
*The percentages were calculated by summing the positive opinions, from 0 upwards.
75.8
71.3
79.9
89.5
76.3
Do you think that in Italy the regulation protects the interests of patients? 
Yes
Not
43.01
56.98
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related to this thematic area is significantly high, with 
the exception of the questions on the meaning of “com-
passionate use”. These responses correlate with the per-
ception of protection by the institutions that regulate 
the process suggesting that good information could in-
crease the degree of trust in people. The recent 2018 
Edelman Trust Barometer seems to confirm this posi-
tion in showing a dramatic distrust mainly at the media 
level, due to the lack of reliability of and transparency 
in information [20]. The data also shows that the mean-
ing of the “compassionate use” procedure is not well 
known to the population, suggesting that in this field 
general information about the possibilities of access to 
experimental treatments, in a regulated manner, need 
to be improved. 
Regarding the right to use unregulated treatments, 
responses were homogeneously distributed between the 
belief that it is a patient right to use treatments out-
side of a regulation and the belief that it is not. These 
responses have no correlation with the answers regard-
ing knowledge of the experimentation process. It seems 
that the perception of this “right” is independent of the 
degree of information about and trust in the institu-
tions: correct information does not seem to influence 
opinion. It would be useful to study more in depth the 
question of “patients’ right”, to see if when responding 
to the question on “right”, people understand the term 
as a general right to access to compassionate use (about 
which they do not seem to have sufficient information) 
or as a general right to try any treatment regardless of 
whether it is located within or outside a shared and 
regulated path. About stem-cell based therapies, the 
respondents in general did not have a good understand-
ing of how these therapies are regulated and the real 
possibilities of use, although the vast majority of them 
had heard of it. The fact that one out of three people is 
unaware that in Italy it is possible to use stem cell-based 
treatments, provided within a regulated process, ex-
plains in part the misunderstanding we have discussed 
above. The same misunderstanding is implicit in US 
“Right To Try” movements, namely that regulators do 
not contemplate a right to try innovative treatments in 
specific circumstances. Information in this sense must 
certainly be expanded and managed responsibly and 
transparently to avoid the risk that patients find them-
selves alone in seeking life-saving treatments at a time 
when they are extremely vulnerable. Interestingly, 72% 
of the sample had heard of patients going abroad to 
undergo treatments unauthorized in Italy.
CONCLUSIONS
Our sample shows a good general knowledge of the 
regulated process of developing new drugs and treat-
ments and a strong confidence in the institutions re-
sponsible for the control. At the same time, it shows 
a lack of knowledge about the regulation of innovative 
treatments based on stem cells. Probably, in this field, 
alongside media overexposure, there has not been suffi-
cient institutional communication. In our view, it is very 
important that there be a multi-level commitment to 
increase awareness among the population of the possi-
bility of using innovative treatments, even if the formal 
testing process has not been completed yet, and that 
unregulated treatment, often offered without guaran-
tees, is very different from the compassionate use or 
hospital exemption of a product. The “Right to Try” 
movements in the US, by using the word “right”, im-
plicitly suggested that a right to try is denied within the 
regulated system, whereas what is denied is exclusively 
use that is not secure, ineffective and that exposes the 
person to unreasonable risks. 
Within a regulated system, compassionate use proce-
dures can be improved to allow easier or faster patients 
access, but this is a different matter.  The possibility of 
relying on risky therapies whose validity is not recog-
nized can perhaps be viewed by some as a right, within 
the conceptual framework of personal autonomy and 
freedom of choice. In our view, the right to try some-
thing whose level of safety and/or risk has not been pre-
viously considered acceptable and that does not follow 
a protocol in line with good clinical practice is not sus-
tainable. Furthermore, autonomy and free choice can-
not be considered as such where there is inadequate 
information and thus the State and the medical com-
munity in general have, at the least, a moral duty to 
educate people through real information about the 
risks they run. The lack of awareness and comprehen-
sion affects dramatically the possibility of free choice, 
especially in situations of strong vulnerability. Trans-
parent and effective communication on how to access 
clinical trials, and on available treatment possibilities, 
within the doctor-patients relationship as well as within 
the institution-citizen relationship is a preventive act to 
protect the vulnerable population. 
A limitation of this study lies certainly in the size of the 
sample that does not allow us to make inferences about 
the general population. It provides, however, some use-
ful food for thought for further research aimed at widely 
exploring the dimension of people’s views on innovative 
therapies, the theme of building a relationship of trust, 
founded primarily on responsible and transparent com-
munication, and the empowerment of people in the era 
of cell therapy and regenerative medicine. 
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